Clinical Trial

TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria

Study acronym: TITAN-HCC
Recruiting
View on ClinicalTrials.gov →
Summary
This is a single-arm, single-center, prospective trial designed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with ipalimab/tuvonralimab (QL1706) in the peri-operative setting for resectable hepatocellular carcinoma exceeding the Milan criteria, and to explore biomarkers predictive of therapeutic response.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-30
Trial Details
NCT Number NCT07268131
Lead Sponsor Fudan University
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 30 participants
Start Date 2025-12-09
Primary Completion 2026-10-31 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31